Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 16 to 20 of 20 results for azacitidine

  1. Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia (TA552)

    Evidence-based recommendations on liposomal cytarabine–daunorubicin (Vyxeos) for untreated acute myeloid leukaemia in adults.

    Technology appraisal guidance
    Published
    19 December 2018
    View recommendations

    Sections for TA552

  2. Past appeals and decisions

    Past technology appraisal appeals and decisions

  3. Magrolimab with azacitidine for untreated myelodysplastic syndromes [ID3978]

    Discontinued Reference number: GID-TA10861

    Technology appraisal guidance
    Discontinued

  4. Gemtuzumab ozogamicin for untreated acute myeloid leukaemia (TA545)

    Evidence-based recommendations on gemtuzumab oxogamicin (Mylotarg) for untreated acute myeloid leukaemia in people aged 15 years and over.

    Technology appraisal guidance
    Published
    14 November 2018
    View recommendations

    Sections for TA545

  5. NICE recommended a new gene therapy, transformative cystic fibrosis medicines and an obesity jab, during election period

    More than 20 pieces of draft and final guidance on a range of medicines and medical conditions were published during the pre-election period.

    News
    Last updated
    10 July 2024